Navigation Links
Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/3/2009

SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the 11th Annual BIO CEO & Investor Conference 2009 on Tuesday, February 10, at 10 a.m. Eastern Time at the Waldorf-Astoria in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration resistant prostate cancers (also known as hormone refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
2. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
3. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
4. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
5. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
6. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
7. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph ... at the Prince Of Wales Private Hospital. The procedure was performed on a ... patient failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc ...
(Date:5/18/2017)... ... , ... NDA Partners Chairman Carl Peck, MD , announced today that ... President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm as ... was former Chief Operating Officer at Anaborex, Senior VP and General Manager of the ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is honored that ... for Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated neurological ... to develop Alzheimer’s disease, while men are at greater risk for Parkinson’s disease. ... bias is the aim of a research program at Worcester Polytechnic Institute (WPI) ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):